Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
German Panobinostat Low-Risk MDS Trial
2009-010403-84Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2009
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of panobinostat and epoetin alfa in myelodysplastic syndrome (MDS) (2 arms), sponsored by Novartis. Primary endpoint: Hematologic improvement of the erythropoietic system at 4 months. Started Aug 2009; status: completed.
02
Drugs
panobinostatepoetin alfa
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2009-010403-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010403-84.